News

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’
We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a ...
Regeneron price target lowered to $940 from $975 at Truist
Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm ...
Healthcare Enforcement Roundup: Developments in False Claims Act and Antikickback Cases
Robert Radick writes his first health care enforcement roundup column for the NYLJ. "This new column will, every two months, ...
Investor's Business Daily on MSN20h
Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats
Eli Lilly stock fell Thursday after the drugmaker cut its full-year profit guidance despite a first-quarter beat.